#exenatide

食事を始めると、インスリンの分泌を促したりするペプチドホルモン群が分泌されます。

アメリカドクトカゲの毒にはこれに似たタンパク質が含まれていて、長期間食事をとらなくても血糖値を維持できることが知られていますが、このタンパク質は糖尿病治療薬としても利用されています。

詳しくは今月の分子「310: インクレチン（Incretins）」をご覧ください。

日本語訳（PDBj）

When you start eating, a group of peptide hormones that stimulate the secretion of insulin is secreted.

The venom of the Gila monster contains a similar protein, which is known to help maintain blood sugar levels even after prolonged fasting. This protein is also used as a treatment for diabetes.

For details, please refer to the Molecule of the Month article 310: Incretins

Original English Article（RCSB PDB）

This class of medications known only by their physiological effects, the “incretin effect” (incretin mimetic) when I graduated from medical school in 1981, may reduce US mortality by 6.4%.

The first incretin mimetic available for clinical use was exenatide (Byetta). It was initially found in the saliva of Gila monsters. Exenatide has a high homology to human GLP-1 the first incretin mimetic to not only cause the incretin effect in healthy individuals but also in individuals with type 2 diabetes. And unlike GLP-1, exenatide is partially resistant to the enzyme that neutralizes GLP-1.

The first weekly incretin mimetic was dulaglutide (Trulicity). Dulaglutude is a unique fusion protein of a modified human GLP-1 peptide linked to a portion of a modified human immunoglobulin. The peptide itself was not effective until fused to the immunoglobulin.

Gli agonisti del recettore del peptide-1 simile al glucagone (GLP-1RA) sono efficaci nel ridurre l’emoglobina glicata e il peso corporeo senza aumentare l’incidenza di reazioni ipoglicemiche, secondo uno studio pubblicato su Frontiers in Endocrinology. Abbiamo portato avanti una metanalisi di rete per valutare oggettivamente l’efficacia e la sicurezza di 10 GLP-1RA approvati per l’uso in tutto…

The recently Published Report titled Exenatide Market: Comprehensive Analysis, Opportunities, Classifications, Applications and Expert Opinions by Axel Reports offers a comprehensive picture of the market from the global view point as well as a descriptive analysis with detailed segmentation, complete research and development history, latest news, offering a forecast and statistic in terms of revenue during the forecast period from 2021-2027. The report covers a comprehensive analysis of key segments, recent trends, competitive landscape, and key factors playing a substantial role in the market are detailed in the report. The report helps vendors and manufacturers to understand the change in the market dynamics over the years.

Get Sample Copy of this Report with the Latest Market Trend and COVID-19 Impact: https://axelreports.com/request-sample/55707

Global Market Segmentation by Top Key-Players: AstraZeneca

NOTE: Consumer behaviour has changed within all sectors of the society amid the COVID-19 pandemic. Industries on the other hand will have to restructure their strategies in order to adjust with the changing market requirements. This report offers you an analysis of the COVID-19 impact on the Exenatide market and will help you in strategising your business as per the new industry norms.

Report offers: 1. Insights into the intact market structure, scope, profitability, and potential. 2. Precise assessment of market size, share, demand, and sales volume. 3. Authentic estimations for revenue generation and Exenatide Market development. 4. Thorough study of Exenatide Market companies including organizational and financial status. 5. Perception of crucial market segments including, forecast study. 6. Acumen of upcoming opportunities and potential threats and risks in the market.

Market segments by Types of, the report covers- Extended-release injectable suspension Fast release injectable suspension Market segments by Applications of, the report covers- Hospital Drug store

The report diversifies the global geographical expanse of the market into five prominent regions as:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

Key Elements Discussed In The Report: The report then discusses important dynamics on the business drivers that have a major impact on the performance are given in the report. The business drivers are important to the business operations and financial results of the industry. All the drivers are determined in the research study using market analysis. The report is comprehensive coverage of the existing and potential markets along with their assessment of their competitive position in the changing market scenario. It scrutinizes in-depth global market trends and outlook coupled with the factors driving the global Exenatide market, as well as those hindering it.

Get Up to 30% Discount on the first purchase of this report @ https://axelreports.com/request-discount/55707

Moreover, the report throws light on the pinpoint analysis of global Exenatide market dynamics. It also measures the sustainable trends and platforms which are the basic roots behind the market growth. With the help of SWOT and Porter’s five analysis, the market has been deeply analyzed. Consumer behavior is assessed with respect to current and upcoming trends. The report takes a detailed note of the major industrial events in past years. These events include several operational business decisions, innovations, mergers, collaborations, major investments, etc.

Customization of the Report: This report can be customized to meet the client’s requirements. Please connect with our sales team ( [email protected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +18488639402 to share your research requirements.

ABOUT Axel Reports:

Axel Reports has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world’s most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Diabete: l’insulina non funziona per prevenire i danni oculari. Il vantaggio spunta con le incretine

La retinopatia diabetica è una delle principali complicanze vascolari del diabete di tipo 2 e la causa più comune di deterioramento visivo negli adulti. La retinopatia diabetica è causata da un danno ai vasi sanguigni del tessuto sensibile alla luce nella parte posteriore dell’occhio. La causa è di solito attribuita a glicemia alta (iperglicemia), ma diversi studi hanno dimostrato che…

Imeglimin: al vaglio la nuova metformina senza tanti effetti collaterali

Il diabete di tipo 2 (T2DM) è una malattia diffusa, che colpisce oltre 400 milioni di persone in tutto il mondo, con proiezioni che includerà più di 600 milioni di persone in tutto il pianeta entro il 2035. Per far fronte a questa preoccupazione globale, quantità significative di tempo, sforzi e denaro sono stati assegnati al trattamento, alla prevenzione e all’istruzione da molte entità,…

Special Spotlight On Diabetes Prescription Drugs: Byetta (exenatide)

Medically reviewed by Victor Nguyen, PharmD, MS on July 10, 2019 — Written by Helen Marshall, BPharm, MRPharmS.

Byetta is a brand-name prescription medication. It’s used with a diet and exercise program to help lower blood sugar levels (glucose) in adults with Type 2 diabetes. Byetta is not currently approved for use in children.

Byetta contains exenatide, which is a type of drug known as a…